Author response to Cunha et al
The need to identify biomarkers to predict immunotherapy response for rare cancers has been long overdue. We aimed to study this in our paper, ‘Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers’. In this response to the Letter to the Editor by Cunha et a...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2021-07-01
|
| Col·lecció: | Journal for ImmunoTherapy of Cancer |
| Accés en línia: | https://jitc.bmj.com/content/9/7/e003299.full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|